Healthcare -
Biotechnology - NASDAQ - US
$ 10.93
-2.41 %
$ 504 M
Market Cap
-3.69
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
UroGen Pharma Ltd.
| Net Income | -127 M |
| Depreciation & Amortization | 1.19 M |
| Capital Expenditures | -295 K |
| Stock-Based Compensation | 13.1 M |
| Change in Working Capital | 4.93 M |
| Others | 13.3 M |
| Free Cash Flow | -97.1 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||
| Net Income | (126.9) | (102.2) | (109.8) | (110.8) | (128.5) | (105.1) | (75.7) | (20.0) | (1.9) | (12.7) | (4.5) | (3.3) |
| Depreciation & Amortization | 1.2 | 1.7 | 1.8 | 1.8 | 2.0 | 1.3 | 0.4 | 0.2 | 0.2 | 0.1 | 30 K | 18 K |
| Deferred Income Tax | 0 | 0 | 0 | 15.3 | 0.4 | (0.6) | 0 | 0 | 0 | 0.2 | 0 | 0 |
| Stock Based Compensation | 13.1 | 9.3 | 10.6 | 23.1 | 28.0 | 30.0 | 30.6 | 6.3 | 2.0 | 0.4 | 0.3 | 0.5 |
| Other Operating Activities | 10.9 | 11.5 | 16.1 | (1.2) | (1.5) | (0.9) | 100 K | 0.2 | 2.7 | 4.1 | 0.2 | 0.2 |
| Change in Working Capital | 4.9 | 3.3 | (6.3) | (13.1) | (6.4) | 4.3 | 7.2 | 3.8 | 1.2 | 0.6 | (0.2) | 13 K |
| Cash From Operations | (96.8) | (76.4) | (87.6) | (84.9) | (105.9) | (71.0) | (37.3) | (9.6) | 4.2 | (7.2) | (4.1) | (2.6) |
| INVESTING CASH FLOW | ||||||||||||
| Capital Expenditures | (0.3) | (0.2) | (0.3) | (0.8) | (1.2) | (0.3) | (0.6) | (0.3) | (0.7) | (0.3) | 24 K | 57 K |
| Other Items | (20.3) | (0.8) | 1.3 | 4.8 | 94.5 | (145.3) | 35.8 | (36.1) | 98 K | 0 | 23 K | 32 K |
| Cash From Investing Activities | (20.6) | (1.0) | 1.1 | 4.1 | 93.2 | (145.6) | 35.3 | (36.4) | (0.8) | (0.3) | 1 K | 89 K |
| FINANCING CASH FLOW | ||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 24.5 | 0 | 95.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.0 | 49.6 | 1.4 | 72.3 | 0.7 | 3.6 | 2.2 | 0.7 | 9 K | 21.6 | 4.3 | 3.5 |
| Cash From Financing Activities | 194.6 | 116.9 | 97.1 | 72.3 | 16.5 | 165.2 | 66.4 | 61.6 | 9 K | 21.6 | 5.0 | 3.5 |
| CHANGE IN CASH | ||||||||||||
| Net Change In Cash | 77.2 | 39.6 | 10.6 | (8.5) | 3.9 | (51.4) | 64.4 | 15.6 | 3.4 | 14.1 | 0.8 | 0.8 |
| FREE CASH FLOW | ||||||||||||
| Free Cash Flow | (97.1) | (76.6) | (87.8) | (85.6) | (107.1) | (71.3) | (37.9) | (9.8) | 3.5 | (7.5) | (4.1) | (2.6) |